Probe • Vol LXII • No. 4 • Sep–Dec 2023 • 47 Prescribing Information The various ingredients of Diabecon act synergistically to achieve effective euglycemic response, which helps in preventing long-term complications of diabetes mellitus. Indications • Prediabetes • In newly detected non–insulin-dependent diabetes mellitus (NIDDM)—type 2 diabetes mellitus: – As a monotherapy or as an adjuvant to other oral antidiabetic drugs • As an adjuvant in insulin-dependent diabetes mellitus (IDDM)—type 1 diabetes mellitus • Type 2 diabetes mellitus with micro- and macrovascular complications: – NIDDM with early retinopathy – NIDDM with microalbuminuria – NIDDM with hyperlipidemia Dosage Tablet Monotherapy: 2 tablets twice daily before food in newly detected type 2 diabetes mellitus. Adjuvant therapy: 1 tablet twice daily before food as an adjuvant to OHAs or insulin. DS Tablet Monotherapy: 1 tablet twice daily before food. Adjuvant therapy: 1 tablet once daily before food. The dosage may be titrated depending on the patient’s response. Adverse Effects No adverse effects have been reported. Contraindications No known contraindications. Special Precautions Diabecon is safe. However, when used as an adjuvant in NIDDM and IDDM, it is advisable to titrate the dose of OHAs and insulin under careful medical supervision. Presentation Tablet: Sealed pack of 60 tablets. DS tablet: Sealed pack of 60 tablets. Pharmacologic Actions of Principal Ingredients 1. Insulin secretagogue and insulinomimetic actions: Diabecon increases insulin secretion through the insulin secretagogue and insulinomimetic actions of M charantia, P marsupium, T cordifolia, T terrestris, A vera, O sanctum, P nigrum, C longa, and A indicum. G sylvestre stimulates endogenous insulin secretion by altering the cell membrane permeability, while B diffusa enhances plasma insulin levels. 2. Antihyperglycemic action: Effective hyperglycemic control is crucially important to prevent the micro- and macrovascular complications of diabetes mellitus. G sylvestre, Shilajeet, C esculenta, S cuminii, T cordifolia, P amarus, Triphala, M charantia, and O sanctum decrease hepatic glucose production and prevent hyperglycemia. P marsupium has hypoglycemic action and reduces glucose absorption from the GI tract. 3. α-Glucosidase inhibitory action: The α-glucosidase inhibitory action retards carbohydrate digestion, an alternate means to reduce postprandial hyperglycemia. Epicatechin, the active principle of P marsupium, along with S cuminii and T cordifolia, has α-glucosidase inhibitory activity and regulates key metabolic enzymes involved in carbohydrate metabolism. 4. Glucose utilization-stimulatory action: Diabecon increases the hepatic and muscle glycogen content. G sylvestre, B diffusa, S cuminii, M charantia, P marsupium, and T cordifolia enhance peripheral utilization of glucose.
RkJQdWJsaXNoZXIy MjAwNDg=